semaglutide and triglycerides reduces the risk of major adverse cardiovascular events consistently across baseline triglyceride levels in patients with type 2 diabetes: Post hoc analyses of the SUSTAIN 6 PIONEER 6 trials Intermountain Health study finds weight

Predictors of treatment response in adolescents with comorbid substance use disorder and attention-deficit/hyperactivity disorder

Sudden fiber increases combined with GLP-1's delayed gastric emptying may worsen nausea or bloating

This isnt about the number on the scale

Results will vary between individuals

We recommend future studies to explore these populations, as semaglutide may have a diminished therapeutic effect in these individuals

Most patients begin experiencing noticeable appetite suppression within one to four weeks of starting semaglutide, a GLP-1 receptor agonist FDA-approved for chronic weight management and type 2 diabetes